GlassScriptPhysician profile
Victor S Chu
NPI 1528039443
$5,402.79
in general payments reported to CMS, 2019-2025
40 companies · $727 in 2025
The $727 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $781 · 2020: $902 · 2021: $757 · 2022: $1,055 · 2023: $617 · 2024: $563 · 2025: $727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,907.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $605.16 | 2021-2025 | |
| Novo Nordisk INC | $494.21 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $471.81 | 2021-2025 | Ubrelvy, Creon, Linzess |
| Amgen INC. | $322.69 | 2019-2025 | Repatha, Otezla, Evenity |
| Sanofi-Aventis U.S. LLC | $284.36 | 2019-2022 | |
| Pfizer INC. | $264.28 | 2020-2025 | |
| Sunovion Pharmaceuticals INC. | $242.02 | 2019-2020 | |
| Glaxosmithkline, LLC. | $213.43 | 2019-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.45 | 2019-2024 | Jardiance |
| Abbott Laboratories | $202.68 | 2021-2025 | Freestyle Libre, Freestyle Libre 3 |
| Allergan, INC. | $190.96 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $173.81 | 2019-2025 | Farxiga, Breztri |
| Teva Pharmaceuticals USA, INC. | $169.69 | 2020-2023 | Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $121.93 | 2021-2025 | Caplyta |
| Organogenesis INC. | $107.14 | 2024 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.